HC Wainwright Has Bearish Estimate for AVDL FY2027 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Stock analysts at HC Wainwright reduced their FY2027 earnings estimates for Avadel Pharmaceuticals in a research report issued on Wednesday, November 13th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings per share of $1.67 for the year, down from their previous forecast of $1.74. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ FY2028 earnings at $1.88 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.03. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 93.34%. The business had revenue of $50.00 million for the quarter, compared to analyst estimates of $48.43 million. During the same quarter in the previous year, the firm posted ($0.41) earnings per share. Avadel Pharmaceuticals’s quarterly revenue was up 624.6% on a year-over-year basis.

A number of other brokerages have also weighed in on AVDL. Oppenheimer boosted their price objective on shares of Avadel Pharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Avadel Pharmaceuticals in a research note on Tuesday. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $24.43.

Avadel Pharmaceuticals Stock Performance

NASDAQ:AVDL opened at $10.91 on Thursday. The firm has a 50-day simple moving average of $13.49 and a two-hundred day simple moving average of $15.02. Avadel Pharmaceuticals has a fifty-two week low of $10.39 and a fifty-two week high of $19.09. The firm has a market cap of $1.05 billion, a P/E ratio of -13.81 and a beta of 1.47.

Institutional Trading of Avadel Pharmaceuticals

Large investors have recently modified their holdings of the company. FMR LLC purchased a new position in Avadel Pharmaceuticals in the third quarter worth about $31,000. Amalgamated Bank bought a new position in shares of Avadel Pharmaceuticals in the 2nd quarter worth approximately $45,000. Quarry LP purchased a new position in shares of Avadel Pharmaceuticals in the second quarter worth approximately $63,000. BNP Paribas Financial Markets grew its position in Avadel Pharmaceuticals by 60.5% during the first quarter. BNP Paribas Financial Markets now owns 4,469 shares of the company’s stock valued at $75,000 after buying an additional 1,685 shares during the period. Finally, Advisors Asset Management Inc. increased its holdings in Avadel Pharmaceuticals by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock valued at $104,000 after buying an additional 2,846 shares during the last quarter. Institutional investors own 69.19% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.